Highlights newsletter 2
This newsletter presents you the following key sessions:
1. Video-interview with Professor Philippe Moreau on results of the Phase 3 Tourmaline-MM1 Study with Ixazomib,
the first oral Proteasome Inhibitor, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
2. Adding eltrombopag to standard severe aplastic anemia treatment improves responses for the first time in 30 years
3. Safety of treatment with pomalidomide and low-dose dexamethasone in patients with Relapsed or Refractory
Multiple Myeloma with renal impairment
4. Ibrutinib is superior to chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia
5. Engineered donor T-cells may eradicate progressive disease after stem cell transplantation in patients with
B-cell malignancies